Herpes simplex virus: Difference between revisions
From IDWiki
(created outline) |
(Initial completion of background section) |
||
Line 1: | Line 1: | ||
+ | * Comprises herpes simplex virus 1 (HSV-1) and HSV-2, which are members of the [[Human herpesvirus]] family |
||
+ | * Cause typical painful vesicular lesions on labia or external genitals |
||
+ | * Occasionally cause a viral encephalitis |
||
+ | |||
== Background == |
== Background == |
||
=== Microbiology === |
=== Microbiology === |
||
− | * |
+ | * Enveloped, double-stranded DNA virus |
+ | * HSV-1 and HSV-2 are morphologically and genetically distinct viruses |
||
+ | * Can be infected with both |
||
=== Epidemiology === |
=== Epidemiology === |
||
+ | * Worldwide distribution, and only found in humans |
||
+ | * Most common cause of genital lesions |
||
+ | * Spread through person-to-person contact with skin or mucosa; not spread via fomits |
||
+ | * HSV-1 is more common, with 90% of adults having antibodies by age 40 |
||
+ | ** Often acquired in childhood in Asia and Africa |
||
+ | ** More common in lower SES populations |
||
+ | * HSV-2 has seroprevalence of 15-20% in US |
||
+ | ** More common in women than men, in HIV-infected people, and in MSM |
||
+ | ** May be subclinical if already infected with HSV-1 |
||
=== Pathophysiology === |
=== Pathophysiology === |
||
+ | * Fusion of envelope and cell membrane is mediated by viral glycoproteins B, C, and D and host cell proteins cellular heparin sulfate, TNF receptors, and immunoglobulins |
||
+ | * Internal capsid is released, which makes its way to the nucleus |
||
+ | * Viral DNA polymerase enzyme and viral DNA helicase are targets of antivirals |
||
+ | * Viral DNA may remain latent in about 10% of nearby neurons, characterized by latency-associated transcripts (LATs) |
||
+ | ** Despite being latent, virus can still be shed in mucosa anywhere from 1/10 to 3/4 of days |
||
+ | * HSV-1 prefers trigeminal ganglia as well as cervical ganglia, or sacral nerve root ganglia if genital |
||
== Clinical Presentation == |
== Clinical Presentation == |
||
+ | * Incubation period usually within 5 days for primary infection |
||
== Diagnosis == |
== Diagnosis == |
Revision as of 11:32, 16 October 2019
- Comprises herpes simplex virus 1 (HSV-1) and HSV-2, which are members of the Human herpesvirus family
- Cause typical painful vesicular lesions on labia or external genitals
- Occasionally cause a viral encephalitis
Background
Microbiology
- Enveloped, double-stranded DNA virus
- HSV-1 and HSV-2 are morphologically and genetically distinct viruses
- Can be infected with both
Epidemiology
- Worldwide distribution, and only found in humans
- Most common cause of genital lesions
- Spread through person-to-person contact with skin or mucosa; not spread via fomits
- HSV-1 is more common, with 90% of adults having antibodies by age 40
- Often acquired in childhood in Asia and Africa
- More common in lower SES populations
- HSV-2 has seroprevalence of 15-20% in US
- More common in women than men, in HIV-infected people, and in MSM
- May be subclinical if already infected with HSV-1
Pathophysiology
- Fusion of envelope and cell membrane is mediated by viral glycoproteins B, C, and D and host cell proteins cellular heparin sulfate, TNF receptors, and immunoglobulins
- Internal capsid is released, which makes its way to the nucleus
- Viral DNA polymerase enzyme and viral DNA helicase are targets of antivirals
- Viral DNA may remain latent in about 10% of nearby neurons, characterized by latency-associated transcripts (LATs)
- Despite being latent, virus can still be shed in mucosa anywhere from 1/10 to 3/4 of days
- HSV-1 prefers trigeminal ganglia as well as cervical ganglia, or sacral nerve root ganglia if genital
Clinical Presentation
- Incubation period usually within 5 days for primary infection
Diagnosis
Management
References
- a b M. Howard, J. W. Sellors, D. Jang, N. J. Robinson, M. Fearon, J. Kaczorowski, M. Chernesky. Regional Distribution of Antibodies to Herpes Simplex Virus Type 1 (HSV-1) and HSV-2 in Men and Women in Ontario, Canada. Journal of Clinical Microbiology. 2003;41(1):84-89. doi:10.1128/jcm.41.1.84-89.2003.